Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain.

Abstract

Opioids are first-line drugs for moderate to severe acute pain and cancer pain. However, these medications are associated with severe side effects, and whether they are efficacious in treatment of chronic nonmalignant pain remains controversial. Medications that act through alternative molecular mechanisms are critically needed. Antagonists of α9α10 nicotinic acetylcholine receptors (nAChRs) have been proposed as an important nonopioid mechanism based on studies demonstrating prevention of neuropathology after trauma-induced nerve injury. However, the key α9α10 ligands characterized to date are at least two orders of magnitude less potent on human vs. rodent nAChRs, limiting their translational application. Furthermore, an alternative proposal that these ligands achieve their beneficial effects by acting as agonists of GABAB receptors has caused confusion over whether blockade of α9α10 nAChRs is the fundamental underlying mechanism. To address these issues definitively, we developed RgIA4, a peptide that exhibits high potency for both human and rodent α9α10 nAChRs, and was at least 1,000-fold more selective for α9α10 nAChRs vs. all other molecular targets tested, including opioid and GABAB receptors. A daily s.c. dose of RgIA4 prevented chemotherapy-induced neuropathic pain in rats. In wild-type mice, oxaliplatin treatment produced cold allodynia that could be prevented by RgIA4. Additionally, in α9 KO mice, chemotherapy-induced development of cold allodynia was attenuated and the milder, temporary cold allodynia was not relieved by RgIA4. These findings establish blockade of α9-containing nAChRs as the basis for the efficacy of RgIA4, and that α9-containing nAChRs are a critical target for prevention of chronic cancer chemotherapy-induced neuropathic pain.

• Authors: Haylie K Romero, Sean B Christensen, Lorenzo Di Cesare Mannelli, Joanna Gajewiak, Renuka Ramachandra, Keith S Elmslie, Douglas E Vetter, Carla Ghelardini, Shawn P Iadonato, Jose L Mercado, Baldomera M Olivera, J Michael McIntosh
• Journal: Proceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 114 Issue 10 Pg. E1825-E1832 (03 07 2017) ISSN: 1091-6490 [Electronic] United States
• PMID: 28223528 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Analgesics, Opioid
• CHRNA10 protein, human
• CHRNA9 protein, human
• Ligands
• Nicotinic Antagonists
• Organoplatinum Compounds
• Peptides
• Receptors, GABA-B
• Receptors, Nicotinic
• Oxaliplatin

Topics

• Analgesics, Opioid (adverse effects)
• Animals
• Cancer Pain (chemically induced, drug therapy, genetics, pathology)
• Humans
• Hyperalgesia (chemically induced, drug therapy, genetics, pathology)
• Ligands
• Mice
• Mice, Knockout
• Neuralgia (chemically induced, drug therapy, genetics, pathology)
• Nicotinic Antagonists (administration & dosage)
• Organoplatinum Compounds (adverse effects)
• Oxaliplatin
• Peptides (administration & dosage)
• Receptors, GABA-B (genetics)
• Receptors, Nicotinic (genetics, metabolism)